A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Sponsor

Mayo Clinic (Other)

Overall Status

Recruiting

CT.gov ID

NCT04144023

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Locations

Arm

Anticipated Duration (Months)

21.5

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma in situ. H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of increasing immune response and protecting against breast cancer.

Condition or Disease	Intervention/Treatment	Phase
Breast Ductal Carcinoma In Situ	Biological: Granulocyte-Macrophage Colony-Stimulating Factor Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC Procedure: Therapeutic Conventional Surgery	Phase 1

Detailed Description

PRIMARY OBJECTIVES:

To determine the safety and tolerability of multi-epitope HER2 peptide vaccine H2NVAC (H2NVAC) given every 2 weeks for 4 cycles in patients with HER2 expressing ductal carcinoma in situ (DCIS) prior to surgery.
To determine the dose level of H2NVAC with maximum systemic and intratumoral immunogenicity as measured by activated HER2-specific T lymphocytes or high-affinity antibodies.

SECONDARY OBJECTIVES:

To determine intratumoral immunogenicity of H2NVAC in patients with HER2-expressing DCIS.
To assess the complete pathological response after 4 cycles of neoadjuvant H2NVAC.
To assess the systemic immunogenicity of H2NVAC in patients with HER2-expressing DCIS.
To assess changes in HER2 expression in the DCIS after 4 cycles of neoadjuvant H2NVAC.
To assess the distribution of the helper T cell response among T helper cell differentiation states.

OUTLINE: This is a dose-escalation study of multi-epitope HER2 peptide vaccine H2NVAC.

Prior to standard of care surgery, patients receive granulocyte macrophage-colony-stimulating factor (GM-CSF) admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day

Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 3, 6, and 12 months after surgery and optionally at 18 and 24 months after surgery.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

43 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase IB Trial of Neoadjuvant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS

Actual Study Start Date :

Apr 1, 2019

Anticipated Primary Completion Date :

Jun 1, 2023

Anticipated Study Completion Date :

Jun 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (multi-epitope HER2 peptide vaccine H2NVAC, GM-CSF) Prior to standard of care surgery, patients receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.	Biological: Granulocyte-Macrophage Colony-Stimulating Factor Given intradermally Other Names: Colony Stimulating Factor 2 Colony Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor Colony-Stimulating Factor 2 CSF CSF2 GM CSF GM-CSF GMCSF Granulocyte Macrophage Colony Stimulating Factor Granulocyte Macrophage Colony-Stimulating Factor Granulocyte-Macrophage Colony Stimulating Factor Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC Given intradermally Other Names: H2NVAC HER2 Peptide Vaccine H2NVAC HER2 Specific Helper T-cell Epitope Vaccine H2NVAC Procedure: Therapeutic Conventional Surgery Undergo standard of care surgery

Arm

Intervention/Treatment

Experimental: Treatment (multi-epitope HER2 peptide vaccine H2NVAC, GM-CSF)

Prior to standard of care surgery, patients receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Biological: Granulocyte-Macrophage Colony-Stimulating Factor

Given intradermally

Other Names:

Colony Stimulating Factor 2

Colony Stimulating Factor, Granulocyte-Macrophage

Colony-Stimulating Factor

Colony-Stimulating Factor 2

CSF

CSF2

GM CSF

GM-CSF

GMCSF

Granulocyte Macrophage Colony Stimulating Factor

Granulocyte Macrophage Colony-Stimulating Factor

Granulocyte-Macrophage Colony Stimulating Factor

Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC

Given intradermally

Other Names:

H2NVAC

HER2 Peptide Vaccine H2NVAC

HER2 Specific Helper T-cell Epitope Vaccine H2NVAC

Procedure: Therapeutic Conventional Surgery

Undergo standard of care surgery

Outcome Measures

Primary Outcome Measures

Adverse events [2 years]
Number of adverse events reported.
Dose limiting toxicities [14 days post vaccination, 2 years]
Measured using criteria from the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events, version 4.0 with grade >= 2 allergic reaction, grade >= 2 autoimmune reaction, grade >= 2 injection site reaction manifesting as an ulceration, grade >= 2 neurologic problem, grade 3+ toxicity, or any one of following changes in left ventricular ejection fraction (LVEF).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) performance status =< 2
Patients must not have received any prior therapy for current DCIS
Note: Patients who received tamoxifen, raloxifene, aromatase inhibitor or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least 2 months prior to baseline study biopsy if they chose to have this collected
Note: Concurrent use of endocrine therapy during the vaccination/preoperative period is not allowed. However, standard adjuvant endocrine therapy with tamoxifen or aromatase inhibitor after completion of vaccination and surgery is allowed
Any degree of HER2 expression as performed on the diagnostic clinical biopsy defined by immunohistochemistry +1, +2, or +3
Histologically confirmed un-resected operable ductal carcinoma in situ with no evidence of lymph node involvement or distant metastasis
Note: suspected microinvasion or definite microinvasion (< 0.1 mm invasion) on core biopsy is allowed
Patients will be asked to have an additional research biopsy prior to the first vaccination. This is not mandatory for participation
Patients must have evidence of at least 1.0 cm of disease extent based on mammogram, ultrasound, or magnetic resonance (MRI) imaging
Absolute neutrophil count (ANC) >= 1500/mm^3 (less than or equal to 28 days prior to registration)
Platelet count >= 75,000/mm^3 (less than or equal to 28 days prior to registration)
Hemoglobin >= 9.0 g/dL (less than or equal to 28 days prior to registration)
Creatinine =< 2 x upper limit of normal (ULN) (less than or equal to 28 days prior to registration)
Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2 x ULN (less than or equal to 28 days prior to registration)
Albumin >= 3 g/dL (less than or equal to 28 days prior to registration)
Negative serum pregnancy test done =< 7 days prior to Registration, for women of childbearing potential only
Willing to employ adequate contraception from the time of Registration through 6 months after the final vaccine cycle
Note: Adequate contraception methods include birth control pills, barrier device, intrauterine device
Capable of understanding the investigative nature, potential risks, and benefits of the study
Capable of providing valid informed consent
Willing to return to enrolling institution for all study visits (immunizations, blood draws, etc)
Willing to provide blood samples for correlative research purposes
Willing to receive a tetanus vaccination if subject has not had one within the past year

Exclusion Criteria:

Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
Pregnant women
Nursing women unwilling to stop breast feeding
Women of child bearing potential who are unwilling to employ adequate contraception from the time of registration through 6 months after the final vaccine cycle
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Immunocompromised patients including patients known to be human immunodeficiency virus (HIV) positive or those on chronic steroids
Note: Must be off systemic steroids greater than or equal to 90 days prior to Registration. However, topical steroids, inhalants or steroid eye drops are permitted
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Uncontrolled acute or chronic medical conditions including, but not limited to the following:
Active infection requiring antibiotics
Congestive heart failure with New York Heart Association class III or IV moderate to severe objective evidence of cardiovascular disease
Myocardial infarction or stroke less than or equal to 6 months prior to registration
Receiving any other investigational agent
Other active malignancy at time of registration or less than or equal to the last three years prior to registration. EXCEPTIONS: Non-melanoma skin cancer or carcinoma-in-situ (e.g. of cervix, prostate)
NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (cytotoxics, monoclonal antibodies, small molecule inhibitors) for their cancer
Known history of autoimmune disease, including type I diabetes
Any prior hypersensitivity or adverse reaction to GM-CSF
History of trastuzumab-related cardiac toxicity requiring interruption or discontinuation of therapy, even if left ventricular ejection fraction (LVEF) fully recovered
Baseline LVEF with a value below 55%
Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment
History of myocardial infarction =< 168 days (6 months) prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life threatening ventricular arrhythmias
History of ipsilateral radiation to the current affected breast with DCIS